Investigating the effects of cannabigerol and cannabidiol on fatty liver disease
Official title: The therapeutic effect of cannabigerol (CBG) with or without cannabidiol (CBD) in diet-induced non-alcoholic fatty liver disease
Funded at University of Northern Colorado · NIH-10794804 · Data updated 2026-11-12
This study is looking at how two natural compounds from cannabis, CBG and CBD, might help improve liver health for people with non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH, by reducing inflammation and damage in the liver.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Northern Colorado NIH-funded |
| Lab location | 1 site (Greeley, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $377,986 |
| NIH project number | 1R15DK131507-01A1 |
| Project ID | NIH-10794804 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals diagnosed with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
✕Less likely to help
Patients with alcoholic liver disease or those not diagnosed with fatty liver disease may not benefit from this research.
What this research studies
This research focuses on the potential therapeutic effects of two non-psychoactive cannabinoids, cannabigerol (CBG) and cannabidiol (CBD), in treating non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH). The study aims to evaluate how these cannabinoids can reduce liver inflammation, fibrosis, and damage caused by diet-induced conditions. Using mouse models, the researchers will assess the impact of CBG and CBD on liver health, immune cell behavior, and specific cellular pathways involved in liver function. The findings could provide insights into new treatment options for patients suffering from these chronic liver diseases.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options for patients with fatty liver disease, potentially improving liver health and reducing disease progression.
How similar studies have gone: While cannabinoids have shown promise in other inflammatory conditions, the specific application of CBG and CBD for NAFLD/NASH is relatively novel and has not been extensively tested.
Where this research is happening
-
University of Northern Colorado
Greeley, United States Active
Researchers
- Principal investigator: Han, Yuyan — University of Northern Colorado
- Study coordinator: Han, Yuyan
Related research
Other NIH-funded projects on the same topics.
-
Role of fat droplets in liver fat and inflammatory signals in NAFLD
A study at Johns Hopkins will explore how fat droplets in the liver influence molecules that drive inflammation and progression of non-alcoholic fatty liver disease (NAFLD) in adults.
-
Them1 Inhibitors to Help Treat Fatty Liver Disease
Aims to develop and test small molecule drugs that block Them1 to help people with non-alcoholic fatty liver disease (NAFLD).
-
How the TET1 gene affects non-alcoholic fatty liver disease
Researchers are looking at whether changes in the TET1 gene and DNA 'tagging' (methylation) play a role in adult non-alcoholic fatty liver disease.
-
Hepatocellular Genetic Clues for Fatty Liver in Hispanic Adults
A large NIH grant helps researchers study why fatty liver develops in Hispanic adults and how genetics interact with lifestyle to affect risk.
-
Toxic fats, vitamin B12 loss, and AHR may drive fatty liver disease
This grant looks at how certain environmental chemicals may trigger liver damage linked to fatty liver disease and how a vitamin found in the blood could be affected.
-
Glutamine and T cells in fatty liver disease
A study explores how liver glutamine levels affect inflammatory CD4+ T cells in fatty liver disease to find potential new ways to reduce liver inflammation.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.